170 related articles for article (PubMed ID: 30716331)
1. Whole-Body Physiologically Based Pharmacokinetic Modeling of Trastuzumab and Prediction of Human Pharmacokinetics.
Bae DJ; Kim SY; Bae SM; Hwang AK; Pak KC; Yoon S; Lim HS
J Pharm Sci; 2019 Jun; 108(6):2180-2190. PubMed ID: 30716331
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
3. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
Khot A; Tibbitts J; Rock D; Shah DK
AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
[TBL] [Abstract][Full Text] [Related]
4. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
Li GF; Wang K; Chen R; Zhao HR; Yang J; Zheng QS
Acta Pharmacol Sin; 2012 Nov; 33(11):1359-71. PubMed ID: 23085739
[TBL] [Abstract][Full Text] [Related]
5. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
[TBL] [Abstract][Full Text] [Related]
6. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin
Quartino AL; Li H; Kirschbrown WP; Mangat R; Wada DR; Garg A; Jin JY; Lum B
Cancer Chemother Pharmacol; 2019 Feb; 83(2):329-340. PubMed ID: 30467591
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs.
Munir A; Azam S; Fazal S; Bhatti AI
J Theor Biol; 2018 Aug; 451():1-9. PubMed ID: 29704489
[TBL] [Abstract][Full Text] [Related]
9. Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds.
Mao J; Ma F; Yu J; Bruyn T; Ning M; Bowman C; Chen Y
Biopharm Drug Dispos; 2023 Aug; 44(4):315-334. PubMed ID: 37160730
[TBL] [Abstract][Full Text] [Related]
10. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
Sadiq MW; Nielsen EI; Khachman D; Conil JM; Georges B; Houin G; Laffont CM; Karlsson MO; Friberg LE
J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):69-79. PubMed ID: 27578330
[TBL] [Abstract][Full Text] [Related]
11. Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance.
Horiuchi K; Ohnishi S; Matsuzaki T; Funaki S; Watanabe A; Mizutare T; Matsumoto S; Nezasa KI; Hasegawa H
J Pharm Sci; 2018 May; 107(5):1443-1453. PubMed ID: 29331382
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate.
Ren C; Wang Y; Zhang M; Kong D; Ning C; Cheng Y; Bian Y; Sun M; Su S; Wang Y; Zhang Y; Lu Y; Li N; Zhao D; Chen X
Pharm Res; 2021 Nov; 38(11):1847-1862. PubMed ID: 34773182
[TBL] [Abstract][Full Text] [Related]
13. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
14. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals.
Shimizu H; Yoshida K; Nakada T; Kojima K; Ogasawara A; Nakamaru Y; Yamazaki H
Drug Metab Dispos; 2019 Feb; 47(2):114-123. PubMed ID: 30420404
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib.
Lin L; Wright MR; Hop CECA; Wong H
Drug Metab Dispos; 2022 Sep; 50(9):1170-1181. PubMed ID: 35779865
[TBL] [Abstract][Full Text] [Related]
17. Prediction of nomegestrol acetate pharmacokinetics in healthy female adolescents and adults by whole-body physiology-based pharmacokinetic modelling and clinical validation.
Post TM; Gerrits M; Kerbusch T; de Greef R
Contraception; 2016 Feb; 93(2):133-8. PubMed ID: 26365792
[TBL] [Abstract][Full Text] [Related]
18. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
Yun YE; Edginton AN
J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
[TBL] [Abstract][Full Text] [Related]
19. A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans.
Bi Y; Deng J; Murry DJ; An G
AAPS J; 2016 Jan; 18(1):228-38. PubMed ID: 26559435
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
Boger E; Fridén M
J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):1-12. PubMed ID: 29878860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
